TScan Therapeutics (NASDAQ:TCRX) Given New $10.00 Price Target at HC Wainwright

TScan Therapeutics (NASDAQ:TCRX - Free Report) had its price target cut by HC Wainwright from $15.00 to $10.00 in a research note issued to investors on Wednesday morning, Marketbeat reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for TScan Therapeutics' FY2029 earnings at $0.32 EPS.

TCRX has been the subject of a number of other research reports. Needham & Company LLC reissued a "buy" rating and set a $9.00 target price on shares of TScan Therapeutics in a research note on Tuesday, April 8th. Barclays dropped their target price on TScan Therapeutics from $14.00 to $3.00 and set an "overweight" rating on the stock in a research report on Friday, March 7th. Wedbush reiterated an "outperform" rating and set a $7.00 price target on shares of TScan Therapeutics in a report on Tuesday, May 6th. Finally, Morgan Stanley reaffirmed an "overweight" rating and set a $10.00 price objective on shares of TScan Therapeutics in a research report on Friday, March 14th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has an average rating of "Buy" and a consensus target price of $8.50.

TScan Therapeutics Stock Up 6.7%

Shares of TCRX stock traded up $0.09 on Wednesday, reaching $1.36. 130,358 shares of the company's stock traded hands, compared to its average volume of 361,618. The company has a market capitalization of $76.68 million, a P/E ratio of -1.28 and a beta of 1.06. TScan Therapeutics has a 12-month low of $1.02 and a 12-month high of $9.69. The company has a debt-to-equity ratio of 0.13, a quick ratio of 9.56 and a current ratio of 9.56. The business's 50 day moving average price is $1.49 and its two-hundred day moving average price is $2.69.

TScan Therapeutics (NASDAQ:TCRX - Get Free Report) last issued its earnings results on Monday, May 12th. The company reported ($0.26) earnings per share for the quarter, beating analysts' consensus estimates of ($0.28) by $0.02. The company had revenue of $2.17 million for the quarter, compared to the consensus estimate of $1.62 million. TScan Therapeutics had a negative return on equity of 58.72% and a negative net margin of 1,188.88%. On average, equities analysts forecast that TScan Therapeutics will post -1.12 earnings per share for the current year.

Institutional Investors Weigh In On TScan Therapeutics

A number of large investors have recently added to or reduced their stakes in TCRX. Prudential Financial Inc. bought a new stake in shares of TScan Therapeutics during the 4th quarter worth $32,000. China Universal Asset Management Co. Ltd. bought a new stake in TScan Therapeutics during the fourth quarter valued at about $32,000. ProShare Advisors LLC bought a new stake in TScan Therapeutics during the fourth quarter valued at about $40,000. Wells Fargo & Company MN increased its stake in shares of TScan Therapeutics by 41.1% in the fourth quarter. Wells Fargo & Company MN now owns 19,540 shares of the company's stock worth $59,000 after purchasing an additional 5,694 shares during the period. Finally, Squarepoint Ops LLC bought a new position in shares of TScan Therapeutics in the fourth quarter worth about $59,000. Institutional investors own 82.83% of the company's stock.

About TScan Therapeutics

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.